Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (180)
  • Open Access


    Harmonics Extraction Scheme for Power Quality Improvement Using Chbmli-Dstatcom Module

    R. Hemalatha1,*, M. Ramasamy2

    Intelligent Automation & Soft Computing, Vol.35, No.2, pp. 1505-1525, 2023, DOI:10.32604/iasc.2023.026301

    Abstract In recent day’s power distribution system is distress from acute power quality issues. In this work, for compensating Power Quality (PQ) disturbances a seven level cascaded H-bridge inverter is implemented in distribution static compensator which protects power quality problems in currents. Distribution Static Compensator (DSTATCOM) aid to enhances power factor and removes total harmonic distortion which is drawn from non-linear load. The D–Q reference theory based hysteresis current controller is employed to generate reference current for compensation of harmonics and reactive power, additionally Probabilistic Neural Network (PNN) classifier is used which easily separates exact harmonics. In the meantime fuzzy logic… More >

  • Open Access


    Research on Dynamic and Static Test Methods for Evaluating the Poisson’s Ratio of Oriented Strand Board

    Yuhao Zhou, Yuhang He, Zhaoyu Shen, Zheng Wang*

    Journal of Renewable Materials, Vol.10, No.12, pp. 3459-3476, 2022, DOI:10.32604/jrm.2022.021251

    Abstract In this article, dynamic method and static method of testing Poisson’s ratio of OSB (Oriented Strand Board) were proposed. Through modal and static numerical analyses, the position where the transverse stress is equal to zero was determined. The binary linear regression method was applied to express the gluing position of the strain gauge as a relational expression that depended on the length-width ratio and width-thickness ratio of the cantilever plate. Then the longitudinal and transverse Poisson’s ratios of OSB were measured by the given dynamic and static methods. In addition, the test results of OSB Poisson’s ratio were analyzed with… More >

  • Open Access


    Numerical Simulation Research on Static Aeroelastic Effect of the Transonic Aileron of a High Aspect Ratio Aircraf

    Hongtao Guo, Changrong Zhang, Binbin Lv, Li Yu*

    CMES-Computer Modeling in Engineering & Sciences, Vol.132, No.3, pp. 991-1010, 2022, DOI:10.32604/cmes.2022.020638

    Abstract The static aeroelastic effect of aircraft ailerons with high aspect ratio at transonic velocity is investigated in this paper by the CFD/CSD fluid-structure coupling numerical simulation. The influences of wing static aeroelasticity and the ‘scissor opening’ gap width between aileron control surface and the main wing surface on aileron efficiency are mainly explored. The main purpose of this paper is to provide technical support for the wind tunnel experimental model of aileron static aeroelasticity. The results indicate that the flight dynamic pressure has a great influence on the static aeroelastic effect of ailerons, and the greater the dynamic pressure, the… More >

  • Open Access


    OLFM4 Inhibits Epithelial–Mesenchymal Transition and Metastatic Potential of Cervical Cancer Cells

    Juan Li*†1, Chunyan Liu‡1, Dawei Li§, Meng Wan, Hong Zhang, Xiaoxia Zheng, Xuemei Jie, Pengju Zhang, Jingjing Li#, Hongchun Hou, Qing Sun*

    Oncology Research, Vol.27, No.7, pp. 763-771, 2019, DOI:10.3727/096504018X15399955297355

    Abstract OLFM4 has been shown to play an important role in tumor initiation and progression. This study aims to investigate the role of OLFM4 in metastatic cervical cancer and its underlying mechanism. Here we discover that OLFM4 expression is significantly reduced in metastatic cervical cancer. Accordingly, overexpression of OLFM4 inhibits epithelial–mesenchymal transition (EMT), migration, and invasion in human cervical cancer cells. To further explore its molecular mechanisms, we reveal that OLFM4 augmentation interferes with mTOR signaling pathway, and the suppressive effects of OLFM4 on cell migration and invasion are largely weakened by phosphatidic acid (PA)-induced mTOR signal activation, which implicates the… More >

  • Open Access


    Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study

    Xiaoting Wei, Lili Mao, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong, Jie Dai, Xuan Wang, Siming Li, Bixia Tang, Bin Lian, Xieqiao Yan, Xue Bai, Li Zhou, Jun Guo, Lu Si

    Oncology Research, Vol.27, No.4, pp. 495-501, 2019, DOI:10.3727/096504018X15331163433914

    Abstract Melanoma is an aggressive malignancy with a poor prognosis. Current studies show that imatinib treatment is a promising approach in treating advanced melanoma patients harboring c-Kit mutations or amplifications. We retrospectively analyzed the clinical medical records of 78 patients with metastatic melanoma harboring c-Kit mutations or amplifications. These patients were treated with imatinib at a dose of 400 mg/day continuously unless intolerable toxicities or disease progression occurred. Endpoints for exploration included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease of control rate (DCR). The median OS and PFS of all patients were 13.1 and 4.2 months,… More >

  • Open Access


    Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels

    Xiuhua Weng*1, Shaohong Luo*1, Shen Lin*, Lixian Zhong, Meiyue Li*, Rao Xin*, Pinfang Huang*, Xiongwei Xu*

    Oncology Research, Vol.28, No.2, pp. 117-125, 2020, DOI:10.3727/096504019X15707883083132

    Abstract To evaluate the cost–utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic nonsmall cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed to compare the lifetime cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE- 042; ClinicalTrials.gov; NCT02220894). Weibull distribution was fitted to simulate the parametric survival functions. Drug costs were collected from official websites, and utility values were obtained from published literature. Total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were computed… More >

  • Open Access


    A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab

    Tsung-Kun Chang*†, Tzu-Chieh Yin‡§, Wei-Chih Su*†, Hsiang-Lin Tsai, Ching-Wen Huang, Yen-Cheng Chen*, Ching-Chun Li*, Po-Jung Chen*, Cheng-Jen Ma, Kuo-Hsiang Chuang#, Tian-Lu Cheng**, Jaw-Yuan Wang*†¶††‡‡§§

    Oncology Research, Vol.28, No.7-8, pp. 801-809, 2020, DOI:10.3727/096504021X16218531628569

    Abstract Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients. Diarrhea is the most common adverse event (AE). The underlying mechanism of irinotecaninduced diarrhea is intestinal mucosal damage caused by SN-38 (active metabolite of irinotecan) hydrolyzed from SN-38G (inactive metabolite) by bacterial -glucuronidase ( G). According to an animal study, silymarin reduces the activity of bacterial G without impairing antitumor efficacy. We conducted a prospective openlabel pilot study to evaluate the effect of silymarin as supplementation in reducing toxicities of mCRC patients undergoing irinotecan-based chemotherapy. We enrolled and randomized 70 mCRC patients receiving first-line… More >

  • Open Access


    Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy

    Hsiang-Lin Tsai*†, Yen-Cheng Chen*‡, Tzu-Chieh Yin*§¶, Wei-Chih Su*‡, Po-Jung Chen*,Tsung-Kun Chang*†, Ching-Chun Li*, Ching-Wen Huang*†, Jaw-Yuan Wang*†‡#**††‡‡

    Oncology Research, Vol.29, No.1, pp. 47-61, 2021, DOI:10.3727/096504022X16451187313084

    Abstract Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism plays a crucial role in the increased susceptibility and toxicity of patients to irinotecan. This retrospective, observational study compared the clinical outcomes and adverse events (AEs) in RAS wild-type metastatic colorectal cancer (mCRC) patients treated with cetuximab or bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation as the first-line therapy. In total, 173 patients with mCRC with RAS wild-type were enrolled. Among them, 98 patients were treated with cetuximab, whereas 75 patients were treated with bevacizumab. All patients received irinotecan dose escalation based on UGT1A1 genotyping. We compared the progression-free survival (PFS),… More >

  • Open Access


    Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer

    Shuai Liu*†1, Lu Lu*†1, Feng Pan, Chunsheng Yang*†, Jing Liang§, Jinfeng Liu, Jian Wang#, Rong Shen**, Fu-Ze Xin††, Nan Zhang*†

    Oncology Research, Vol.29, No.1, pp. 25-31, 2021, DOI:10.3727/096504022X16427607626672

    Abstract Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free survival (PFS) was evaluated using the… More >

  • Open Access


    Minimizing Buoyancy Factor of Metallic Pressure-Hull Subjected to Hydrostatic Pressure

    Mahmoud Helal1,2, Elsayed Fathallah3,4, Abdulaziz H Alghtani1, Hussein Shawki Osman5, Jong Wan Hu6,7,*, Hasan Eleashy8

    Intelligent Automation & Soft Computing, Vol.35, No.1, pp. 769-793, 2023, DOI:10.32604/iasc.2023.025618

    Abstract To increase the payload, reduce energy consumption, improve work efficiency and therefore must accordingly reduce the total hull weight of the submersible. This paper introduces a design optimization process for the pressure-hull of submarines under uniform external hydrostatic pressure using both finite element analysis (FEA) and optimization tools. A comprehensive study about the optimum design of the pressure hull, to minimize the weight and increase the volume, to reach minimum buoyancy factor and maximum operating depth minimizing the buoyancy factor (B.F) is taken as an objective function with constraints of plate and frame yielding, general instability and deflection. The optimization… More >

Displaying 21-30 on page 3 of 180. Per Page